Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2/Neu+ Uterine Serous Carcinoma”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Study completedNCT01367002
What this trial is testing

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Who this might be right for
Endometrial Cancer
Yale University 61
Large-scale testing (Phase 3)Looking for participantsNCT05256225
What this trial is testing

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Who this might be right for
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI) 360
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Testing effectiveness (Phase 2)Looking for participantsNCT02491099
What this trial is testing

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Who this might be right for
HER2/Neu+ Uterine Serous Carcinoma
Yale University 50
Early research (Phase 1)Active Not RecruitingNCT02208375
What this trial is testing

MTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Who this might be right for
BRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more
M.D. Anderson Cancer Center 159
Early research (Phase 1)Looking for participantsNCT04389632
What this trial is testing

Sigvotatug Vedotin in Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer 1,006
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Early research (Phase 1)Ended earlyNCT05194072
What this trial is testing

Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms+8 more
Seagen, a wholly owned subsidiary of Pfizer 250
Early research (Phase 1)Ended earlyNCT04665921
What this trial is testing

SGN-STNV in Advanced Solid Tumors

Who this might be right for
Carcinoma, Non-Small Cell LungHER2 Negative Breast NeoplasmsOvarian Neoplasms+9 more
Seagen Inc. 111